From: Reuters
Published May 30, 2008 01:43 AM

Roche says Herceptin with Pertuzumab "impressive"

ZURICH (Reuters) - Roche Holding AG's Herceptin combined with Pertuzumab showed "impressive results" in a Phase II breast cancer trial, the Swiss drugmaker said on Friday.

For the Roche statement, click on:

The company also cited a late-stage trial showing that Herceptin treatment prevented disease progression in women with aggressive metastatic breast cancer.

In the trial, women with breast cancer received either Herceptin -- which is also known as trastuzumab -- with Xeloda, another Roche drug, or Xeloda alone.


The data are due to be presented at an American Society of Clinical Oncology (ASCO) meeting.

(Reporting by Thomas Atkins; Editing by Paul Bolding)

Terms of Use | Privacy Policy

2018©. Copyright Environmental News Network